Increased visceral to subcutaneous fat ratio is associated with decreased overall survival in patients with metastatic melanoma receiving anti-angiogenic therapy
- PMID: 26690825
- PMCID: PMC6586412
- DOI: 10.1016/j.suronc.2015.09.002
Increased visceral to subcutaneous fat ratio is associated with decreased overall survival in patients with metastatic melanoma receiving anti-angiogenic therapy
Abstract
Background: Body fat distribution is an emerging prognostic indicator in patients treated with anti-angiogenic (AA) therapy. We sought to evaluate the association of visceral and subcutaneous fat with progression free survival (PFS) and overall survival (OS) in patients with metastatic melanoma treated with AA therapy.
Methods: Stage IV melanoma patients received bevacizumab ± interferon-alpha. Total abdominal fat, visceral fat area (VFA) and subcutaneous fat area (SFA) were measured at L3-L4 on CT images (cm(2)). PFS and OS were estimated by the Kaplan-Meier method. Cox proportional hazards model was used to assess the association of fat and clinical variables with PFS and OS. Prediction accuracy was evaluated using receiver operating characteristic curve with area under the curve (AUC).
Results: Forty-two patients were evaluated. Median VFA/SFA and body mass index (BMI) were used to group patients into high and low cohorts. PFS and OS were significantly decreased in patients with high VFA/SFA versus low (PFS, p=0.009; OS, p = 0.007), but not for BMI (PFS, p=0.774; OS, p=0.881). VFA/SFA, LDH and liver metastasis (LM) were predictors of PFS and OS on multivariate analysis. A prognostic score combining VFA/SFA, LDH, and presence or absence of LM had a higher accuracy for predicting PFS at 3 months (AUC 0.759) and OS at 24 months (AUC 0.846) than LDH and LM alone (PFS, AUC 0.705; OS, AUC 0.786).
Conclusion: Increased VFA/SFA is associated with decreased PFS and OS in patients with metastatic melanoma treated with AA therapy, indicating body fat distribution is an important prognostic factor.
Keywords: Abdominal fat; Anti-angiogenic therapy; Melanoma; Visceral fat.
Copyright © 2015 Elsevier Ltd. All rights reserved.
Figures



Similar articles
-
Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer.Gut. 2010 Mar;59(3):341-7. doi: 10.1136/gut.2009.188946. Epub 2009 Oct 15. Gut. 2010. PMID: 19837679
-
Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer.Gynecol Oncol. 2014 Apr;133(1):11-5. doi: 10.1016/j.ygyno.2014.01.031. Gynecol Oncol. 2014. PMID: 24680585
-
Clinical Impact of Abdominal Fat Distribution on Prognosis After Esophagectomy for Esophageal Squamous Cell Carcinoma.Ann Surg Oncol. 2016 Apr;23(4):1387-94. doi: 10.1245/s10434-015-5018-x. Epub 2015 Dec 14. Ann Surg Oncol. 2016. PMID: 26668084
-
Computed Tomography-Defined Fat Composition as a Prognostic Marker in Gastric Adenocarcinoma: A Systematic Review and Meta-Analysis.Dig Dis. 2023;41(2):177-186. doi: 10.1159/000527532. Epub 2022 Oct 13. Dig Dis. 2023. PMID: 36228589 Free PMC article.
-
The Effects of Exercise Interventions on Ectopic and Subcutaneous Fat in Patients with Type 2 Diabetes Mellitus: A Systematic Review, Meta-Analysis, and Meta-Regression.J Clin Med. 2024 Aug 23;13(17):5005. doi: 10.3390/jcm13175005. J Clin Med. 2024. PMID: 39274218 Free PMC article. Review.
Cited by
-
The Clinical Value of Nutritional Care before and during Active Cancer Treatment.Nutrients. 2021 Apr 5;13(4):1196. doi: 10.3390/nu13041196. Nutrients. 2021. PMID: 33916385 Free PMC article. Review.
-
Adipose tissue area as a predictor for the efficacy of apatinib in platinum-resistant ovarian cancer: an exploratory imaging biomarker analysis of the AEROC trial.BMC Med. 2020 Oct 5;18(1):267. doi: 10.1186/s12916-020-01733-4. BMC Med. 2020. PMID: 33012286 Free PMC article.
-
Obesity as defined by waist circumference but not body mass index is associated with higher renal mass complexity.Urol Oncol. 2017 Nov;35(11):661.e1-661.e6. doi: 10.1016/j.urolonc.2017.06.058. Epub 2017 Aug 7. Urol Oncol. 2017. PMID: 28797586 Free PMC article.
-
Establishment of normative biometric data for body composition based on computed tomography in a North American cohort.Clin Nutr. 2021 Apr;40(4):2435-2442. doi: 10.1016/j.clnu.2020.10.046. Epub 2020 Oct 29. Clin Nutr. 2021. PMID: 33176926 Free PMC article.
-
Re-Evaluating the Effects of Obesity on Cancer Immunotherapy Outcomes in Renal Cancer: What Do We Really Know?Front Immunol. 2021 Aug 5;12:668494. doi: 10.3389/fimmu.2021.668494. eCollection 2021. Front Immunol. 2021. PMID: 34421889 Free PMC article. Review.
References
-
- Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004. August; 4(8):579–91. - PubMed
-
- Samanic C, Gridley G, Chow WH, Lubin J, Hoover RN, Fraumeni JF Jr. Obesity and cancer risk among white and black United States veterans. Cancer Causes Control. 2004. February; 15(1):35–43. - PubMed
-
- Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008. February 16; 371(9612):569–78. - PubMed
-
- Miyazawa-Hoshimoto S, Takahashi K, Bujo H, Hashimoto N, Saito Y. Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects. Diabetologia. 2003. November; 46(11):1483–8. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical